Analysis of Relative Factors on Tumor Reocurrance or Matastasis for Over Five years Survival Patients after Esophageal Carcinoma Resection_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZHAOHai-long ¹ , XUEJi-jun ¹ , ZHENGFeng-zhang ¹ , ZHUXiao-kang ¹ , XIONGHai-ke ² , YUANJi-bao ² , ZHUZi-jiang ¹

1. The Second Department of Thoracic Surgery, Gansu Province Academy of Medical Science, Tumor Hospital of Gansu Province, Lanzhou 730050, P.R.China;
2. Department of Thoracic Surgery, Gansu College of Chinese Medicine, Lanzhou 730000, P.R.China;

Corresponding author：

Keywords：

Esophageal carcinoma; Surgical therapy; Long-term survival; Recurrence and metastasis

DOI：

10.7507/1007-4848.20160131

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the relative factors on tumor reocurrance or matastasis for over five years survival patients after esophageal carcinoma resection. Method We followed up the patients underwent esophageal carcinoma resection in our hospital and discharged between October 1997 and October 2002. We analyzed the clinical data of 181 over five years survival patients with complete follow-up data. There were 148 males and 33 females with the mean age of 63.9 years ranging from 60-70 years. We summarized the follow-up data and carried on the univariate analysis of relatively recurrent data. Result The result of univariate analysis showed that tumor recurrence as well as matastasis statistically related with degree of differentiation, pTNM stage, whether there was lymph node metastasis or not, and the number of lymph node metastasis (P<0.05), but not with gender, age, the length of tumor, the site of tunor, or other clinicopathologic characteristics (P>0.05). Conclusion The main factors influencing over five years survival rate after esophageal carcinoma resection are pTNM staging when operating, lymph node metastasis or not, and the number of lymph node metastasis.

Citation： ZHAOHai-long, XUEJi-jun, ZHENGFeng-zhang, ZHUXiao-kang, XIONGHai-ke, YUANJi-bao, ZHUZi-jiang. Analysis of Relative Factors on Tumor Reocurrance or Matastasis for Over Five years Survival Patients after Esophageal Carcinoma Resection. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2016, 23(6): 546-549. doi: 10.7507/1007-4848.20160131 Copy

1.	Earlam R, Cunha-Melo JR. Esophageal squamous cell carcinoma: A critical review of surgery. Br J Surg, 1980, 67:381-390.
2.	Wang PY, Chen KY. Surgical treatment of carcinoma of the esophageal and cardia among the Chinese. Ann Thorac Surg, 1983, 6: 3-11.
3.	Sanz L, Gonzalez JL, Miyar A, et al. Pattern of recurrence after esophageal resection for cancer. Hepatogastr Enterol, 1999, 46: 2393-2397.
4.	Osugi H, Takemura M, Higashino M, et al. Causes of death and pattern of recurrence after esophagectomy and extended lymphadenectomy for squamous cell carcinoma of the thoracic esophagus. Oncol Rep, 2003, 10: 81-87.
5.	Fahn HJ, Wang LS, Huang BS, et al. Tumor recurrence in long-term survivors after treatment of carcinoma of the esophagus. Ann Thorac Surg, 1994, 57: 677-681.
6.	Huang GJ, Wang LW, Zhang DW, et al. Late results of surgical treatment for carcinoma of the esophagus. Dis Esoph, 1988, 8: 641-644.
7.	Kato H. Lymph node dissection for thorac esophageal carcino-ma:Two-and three-field lymph node dissection. Ann Chir Cynaecol, 1995, 84(2): 193-199.
8.	Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation orlymphadenectomy extent. Ann Surg, 2008, 247(2): 365-371.
9.	Romeo B, Mark K. Diseases of the esophagus. Futura Publishing co Inc. 1990.
10.	Korst RJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg, 1998, 115: 660-669.
11.	Ellis FH Jr, Heatley GJ, Krasna MJ, et al. Esophagogastrectomy for carcinoma of the esophagus and cardia a comparison of findings and results after standard resection in three consecutive eight year intervals with improved staging criteria. J Thorac Cardiovasc Surg, 1997, 113: 836-846.
12.	Gu Y, Swisher SG, Ajani JA, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer, 2006, 106: 1017-1025.
13.	Wilson M, Rosato EL, Chojnacki KA, et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res, 2008, 146(1): 11-15.
14.	Korst RJ, Rusch VW, Venkatraman W, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg, 1998, 115: 660-670.
15.	Bogoevski D, Onken F, Koenig A, et al. Is it time for a new TNM classification in esophageal carcinoma? Ann Surg, 2008, 247(4): 633-641.
16.	Greenstein AJ, Litle VR, Swanson SJ, et al. Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg, 2008, 206(2): 239-246.
17.	Hsu CP, Chen CY, Hsia JY, et al. Prediction of prognosis by the extent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus. Eur J Cardiothorac Surg, 2001, 19(1): 10-13.
18.	Kunisaki C, Akiyama H, Nomura M, et al. Developing an appropriate staging system for esophageal carcinoma. J Am Coll Surg, 2005, 201(6): 884-890.
19.	Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg, 2003, 125 (5): 1103-1113.
20.	Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg, 2006, 132(6): 1374-1381.
21.	Wilson M, Rosato EL, Chojnacki KA, et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res, 2008, 146(1): 11-15.

1. Earlam R, Cunha-Melo JR. Esophageal squamous cell carcinoma: A critical review of surgery. Br J Surg, 1980, 67:381-390.
2. Wang PY, Chen KY. Surgical treatment of carcinoma of the esophageal and cardia among the Chinese. Ann Thorac Surg, 1983, 6: 3-11.
3. Sanz L, Gonzalez JL, Miyar A, et al. Pattern of recurrence after esophageal resection for cancer. Hepatogastr Enterol, 1999, 46: 2393-2397.
4. Osugi H, Takemura M, Higashino M, et al. Causes of death and pattern of recurrence after esophagectomy and extended lymphadenectomy for squamous cell carcinoma of the thoracic esophagus. Oncol Rep, 2003, 10: 81-87.
5. Fahn HJ, Wang LS, Huang BS, et al. Tumor recurrence in long-term survivors after treatment of carcinoma of the esophagus. Ann Thorac Surg, 1994, 57: 677-681.
6. Huang GJ, Wang LW, Zhang DW, et al. Late results of surgical treatment for carcinoma of the esophagus. Dis Esoph, 1988, 8: 641-644.
7. Kato H. Lymph node dissection for thorac esophageal carcino-ma:Two-and three-field lymph node dissection. Ann Chir Cynaecol, 1995, 84(2): 193-199.
8. Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation orlymphadenectomy extent. Ann Surg, 2008, 247(2): 365-371.
9. Romeo B, Mark K. Diseases of the esophagus. Futura Publishing co Inc. 1990.
10. Korst RJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg, 1998, 115: 660-669.
11. Ellis FH Jr, Heatley GJ, Krasna MJ, et al. Esophagogastrectomy for carcinoma of the esophagus and cardia a comparison of findings and results after standard resection in three consecutive eight year intervals with improved staging criteria. J Thorac Cardiovasc Surg, 1997, 113: 836-846.
12. Gu Y, Swisher SG, Ajani JA, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer, 2006, 106: 1017-1025.
13. Wilson M, Rosato EL, Chojnacki KA, et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res, 2008, 146(1): 11-15.
14. Korst RJ, Rusch VW, Venkatraman W, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg, 1998, 115: 660-670.
15. Bogoevski D, Onken F, Koenig A, et al. Is it time for a new TNM classification in esophageal carcinoma? Ann Surg, 2008, 247(4): 633-641.
16. Greenstein AJ, Litle VR, Swanson SJ, et al. Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg, 2008, 206(2): 239-246.
17. Hsu CP, Chen CY, Hsia JY, et al. Prediction of prognosis by the extent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus. Eur J Cardiothorac Surg, 2001, 19(1): 10-13.
18. Kunisaki C, Akiyama H, Nomura M, et al. Developing an appropriate staging system for esophageal carcinoma. J Am Coll Surg, 2005, 201(6): 884-890.
19. Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg, 2003, 125 (5): 1103-1113.
20. Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg, 2006, 132(6): 1374-1381.
21. Wilson M, Rosato EL, Chojnacki KA, et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res, 2008, 146(1): 11-15.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Analysis of Relative Factors on Tumor Reocurrance or Matastasis for Over Five years Survival Patients after Esophageal Carcinoma Resection

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content